Partnerships Critical To Building China’s R&D Ecosystem (Pt.1)
This article was originally published in PharmAsia News
Executive Summary
China has outlined the main goals for its 13th Five-Year Plan, under which the pharmaceutical sector is seen moving in the direction of increased innovation, and the government seems set to bring biologic medicine development to a new strategic level. But building a healthy ecosystem for drug development will require strong collaboration between multinational pharmaceutical companies and their domestic peers, MNCs told a recent forum in Shanghai.
You may also be interested in...
Key Role For China As Sanofi’s Emerging Markets Business Grows
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.